Репозиторий OAI—PMH
Репозиторий Российская Офтальмология Онлайн по протоколу OAI-PMH
Конференции
Офтальмологические конференции и симпозиумы
Видео
Видео докладов
| Реферат RUS | Литература | Полный текст |
Борискина Л.Н., Гуро М.Ю., Потапова В.Н., Мелихова И.А., Полякова В.Р.
Анализ результатов лечения диффузного диабетического макулярного отека
1. Балашевич Л.И., Измайлов А.С. Диабетическая офтальмопатия.-Санкт-Петербург, 2012.-396 с.
2. Романенко И.А., Черкасова В.В., Егоров Е.А. Диабетический макулярный отек. Классификация, клиника, лечение//РМЖ Клиническая офтальмология.-2011.-Т.12.-№1.-С.44-48.
3. Шадричев Ф.Е., Шкляров Е.Б., Григорьева Н.Н. Использование анти-VEGF терапии в лечении диабетического макулярного отека // Офтальмологические ведомости.-2011.-Т.4.-№1.-С.83-93.
4. Шишкин М.М., Юлдашева Н.М. Интравитреальное введение ингибиторов ангиогенеза как этап щадящей витреоретинальной хирургии пролиферативной диабетической ретинопатии //Вестник Национального медико-хирургического центра им. Н.И. Пирогова.-2011.-Т.6.-№1.-С.77-81.
5. Bresnick G.H. Diabetic maculopathy. A critical review highlighting diffuse macular edema //Ophthalmol.-1983.-V.90.-N11.-P.1301-1317.
6. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal grid photocoagulation for diabetic macular edema //Ophthalmol.-2008.-V.115.-P.1447-1459.
7. Karim R., Tang B. Use of antivascular endothelial growth factor for diabetic macular edema //Clinical Ophthalmology. – 2010. – Vol. 4. – P. 493–517.
8. Lightman S., Towler H.M. Diabetic retinopathy //Clin. Cornerstone. – 2003. – Vol. 5. – P. 12–21.
9. Mason J.O. et al. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006 Oct; 142(4): 685–8.
10. Massin P., Bandello F., Garroeg J.G., Hansen L.L. et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month randomized, controlled, double – masked, multicenter phase II study// Diabetes Care.-2010.-V.33.-N11/-P.2399-2405.
11. McDonald H.R., Schatz H. Visual loss after panretinal photocoagulation for proliferative diabetic retinopathy // Ophthalmol.-1985.-V.92.-P.388-393.
12. Mitchell P., Bandello F., Schmidt-Erfurth U., Lang G.E. et al. The Restore Study Ranibizumab Monotherapy or Combined witch Laser versus Laser monotherapy for Diabetic Macular Edema // Ophthalmol.-2011.-V.118.-N4.-P.615-625.
13. Moradian S. et al. Intravitreal Bavacizumab in active progressive proliferative diabetic retinopathy // Graef.Arch.Clin.Exp.Ophthalm. – 2008. – Vol. 246(12). – P. 1699–1705.
14. Nguen Q.D., Shah S.M., Khwaja A.A., Channa R. et al. Two – year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study // Ophthalmol.-2010.-V.117.-N11.-P.2146-2151.
15. Olk R.J. Modified grid argon (blue – green) laser photocoagulation for diffuse diabetic macular edema// Ophthalmol.-1986.-V.93.-N7.-P.938-950.
16. Otani T., Kishi S., Maruyama Y. Patterns of diabetic macular edema witch optical coherence tomography //Am. J. Ophthalmol.-1999.-V.127.-P.688-693.
17. Phothocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study. Report number 1. Early Treatment Diabetic Retinopathy Study group //Arch. of Opthalmol.-1985.-V.103.-N.12.-P. 1796-1806.
18. Santos A.R., Gomes S.C., Figuera J., Nunes S. et al. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema//Ophtalmologica -2014.-V.231.-P.16-22.
19. Simo R. et al. Angiogenic and antiangiogenic factors in proliferative diabetic retino- pathy // Curr. Diabet. Rev. – 2006. – Vol. 2. – P. 71–98.
20. Soliman W., Sander B., Jorgensen T.M. Enhanced optical coherence patterns of diabetic macular edema and their correlation witch the pathophysiology //Acta Ophthalmol. Scand.-2007.-V.85.-P.613-617.
21. Wirostko B.,Wong T.Y., Simo R. Vascular endothelial growth factor and diabetic complications // Prog. Retin. Eye Res. – 2008. – Vol. 27. – P. 608–621.
2. Романенко И.А., Черкасова В.В., Егоров Е.А. Диабетический макулярный отек. Классификация, клиника, лечение//РМЖ Клиническая офтальмология.-2011.-Т.12.-№1.-С.44-48.
3. Шадричев Ф.Е., Шкляров Е.Б., Григорьева Н.Н. Использование анти-VEGF терапии в лечении диабетического макулярного отека // Офтальмологические ведомости.-2011.-Т.4.-№1.-С.83-93.
4. Шишкин М.М., Юлдашева Н.М. Интравитреальное введение ингибиторов ангиогенеза как этап щадящей витреоретинальной хирургии пролиферативной диабетической ретинопатии //Вестник Национального медико-хирургического центра им. Н.И. Пирогова.-2011.-Т.6.-№1.-С.77-81.
5. Bresnick G.H. Diabetic maculopathy. A critical review highlighting diffuse macular edema //Ophthalmol.-1983.-V.90.-N11.-P.1301-1317.
6. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal grid photocoagulation for diabetic macular edema //Ophthalmol.-2008.-V.115.-P.1447-1459.
7. Karim R., Tang B. Use of antivascular endothelial growth factor for diabetic macular edema //Clinical Ophthalmology. – 2010. – Vol. 4. – P. 493–517.
8. Lightman S., Towler H.M. Diabetic retinopathy //Clin. Cornerstone. – 2003. – Vol. 5. – P. 12–21.
9. Mason J.O. et al. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006 Oct; 142(4): 685–8.
10. Massin P., Bandello F., Garroeg J.G., Hansen L.L. et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month randomized, controlled, double – masked, multicenter phase II study// Diabetes Care.-2010.-V.33.-N11/-P.2399-2405.
11. McDonald H.R., Schatz H. Visual loss after panretinal photocoagulation for proliferative diabetic retinopathy // Ophthalmol.-1985.-V.92.-P.388-393.
12. Mitchell P., Bandello F., Schmidt-Erfurth U., Lang G.E. et al. The Restore Study Ranibizumab Monotherapy or Combined witch Laser versus Laser monotherapy for Diabetic Macular Edema // Ophthalmol.-2011.-V.118.-N4.-P.615-625.
13. Moradian S. et al. Intravitreal Bavacizumab in active progressive proliferative diabetic retinopathy // Graef.Arch.Clin.Exp.Ophthalm. – 2008. – Vol. 246(12). – P. 1699–1705.
14. Nguen Q.D., Shah S.M., Khwaja A.A., Channa R. et al. Two – year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study // Ophthalmol.-2010.-V.117.-N11.-P.2146-2151.
15. Olk R.J. Modified grid argon (blue – green) laser photocoagulation for diffuse diabetic macular edema// Ophthalmol.-1986.-V.93.-N7.-P.938-950.
16. Otani T., Kishi S., Maruyama Y. Patterns of diabetic macular edema witch optical coherence tomography //Am. J. Ophthalmol.-1999.-V.127.-P.688-693.
17. Phothocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study. Report number 1. Early Treatment Diabetic Retinopathy Study group //Arch. of Opthalmol.-1985.-V.103.-N.12.-P. 1796-1806.
18. Santos A.R., Gomes S.C., Figuera J., Nunes S. et al. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema//Ophtalmologica -2014.-V.231.-P.16-22.
19. Simo R. et al. Angiogenic and antiangiogenic factors in proliferative diabetic retino- pathy // Curr. Diabet. Rev. – 2006. – Vol. 2. – P. 71–98.
20. Soliman W., Sander B., Jorgensen T.M. Enhanced optical coherence patterns of diabetic macular edema and their correlation witch the pathophysiology //Acta Ophthalmol. Scand.-2007.-V.85.-P.613-617.
21. Wirostko B.,Wong T.Y., Simo R. Vascular endothelial growth factor and diabetic complications // Prog. Retin. Eye Res. – 2008. – Vol. 27. – P. 608–621.
Страница источника: 86-90
Каталог
Продукции
Организации
Офтальмологические клиники, производители и поставщики оборудования
Издания
Периодические издания
Партнеры
Проекта Российская Офтальмология Онлайн





















